reports
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update...
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Early as this Month FF Recently Filed a Utility Patent Application for a Blockchain-and-Web3-Based Car Sharing and Short-Term Rental System.FF is scheduled to report its third quarter financial results for 2025 after market close on Thursday, November 13, 2025, and will hold an earnings call at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) ...
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on November 12, 2025, at 2:00 p.m. U.S. Pacific Standard Time (November 13, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover fi...
Ensurge Micropower ASA - Mandatory Notice of Trade for Primary Insider...
Ensurge Micropower ASA - Mandatory Notice of Trade for Primary Insiders Reference is made to the stock exchange announcement from Ensurge Micropower ASA ("Ensurge" or the "Company") today regarding a private placement of shares in the Company raising NOK 100 million at a subscription price of NOK 0.90 per share (the "Private Placement"). The following primary insiders (and closely associated companies) were allocated shares in the Private Placement: * AS Mascot Holding, close associate of Alexander Munch-Thore (Chairperson of the Board)* Coretech AS, close associate of Thomas Ramm (Board m...
Ensurge Micropower ASA - Key information relating to possible repair i...
Ensurge Micropower ASA - Key information relating to possible repair issue/subsequent offering Oslo, 9 November 2025 Reference is made to the stock exchange announcement from Ensurge Micropower ASA ("Ensurge" or the "Company") today regarding a private placement of shares in the Company raising NOK 100 million at a subscription price of NOK 0.90 per share (the "Private Placement") and a possible subsequent offering, raising up to NOK 20 million, at the same subscription price as in the private placement (the "Subsequent Offering"), subject to approval by an Extraordinary General Meeting t...
Ensurge Micropower ASA – Private Placement successfully placed
Ensurge Micropower ASA – Private Placement successfully placed NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, Norway, 9 November 2025 Reference is made to the stock exchange announcements published on 6 November 2025 and 7 November 2025 (the “Announcements”) by Ensurge Micropower ASA ("Ensu...
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2...
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies an...
RadNet Reports Third Quarter Financial Results with Record Quarterly R...
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the...
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
- ABGSC Shipping & Transport Research
- Olav Bakke
- Petter Haugen
- ABGSC Shipping & Transport Research
- Olav Bakke
- Petter Haugen
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driv...
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Associat...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Retail Research
- Henrik Bartnes
- Petter Nystrøm
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.